Brazilian families with at least three affected patients. The findings from the present report confirm nonallelic heterogeneity for LGMD and suggest that in our population about 33% ofthe LGMD families are caused by mutations in the 15q gene, 33% in the 2p gene, 17% by mutations in the adhalin gene, and less than 10% may be by mutations at the 13q locus. They also suggest that there is at least one other gene responsible for this phenotype. In addition, the main clinical features of the different forms are discussed.
LGMD genes have been tested in 13 Brazilian families with at least three affected patients. The findings from the present report confirm nonallelic heterogeneity for LGMD and suggest that in our population about 33% ofthe LGMD families are caused by mutations in the 15q gene, 33% in the 2p gene, 17% by mutations in the adhalin gene, and less than 10% may be by mutations at the 13q locus. They also suggest that there is at least one other gene responsible for this phenotype. In addition, the main clinical features of the different forms are discussed.
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Autosomal recessive limb-girdle muscular dystrophies (AR LGMD) represent a group of muscle diseases with a wide spectrum of clinical severity. In the most severe form ofAR LGMD, onset occurs usually between 3 and 5 years; the progression is very rapid with loss ofambulation usually before the third decade. Since this form clinically resembles Xp2 1 Duchenne muscular dystrophy (DMD), it has been called "Duchenne-like muscular dystrophy, DLMD" or "severe childhood autosomal recessive muscular dystrophy, SCARMD'.l In the milder forms (LGMD), onset may be in the first, second, or even third decade; the loss of ambulation usually occurs after the third decade and longevity may be reduced or nearly normal. There is significant variability of clinical symptoms in unrelated patients and within families. ' 5 Despite extensive clinical, epidemiological, and pathological studies, it is still impossible to distinguish the different forms ofAR LGMD. It is now generally accepted that the diagnostic controversies involving this group of diseases will only be resolved when the genes responsible are identified and cloned and their specific mutations are determined.
Several genes have been tested as candidates for AR LGMD, such as genes which show homology to dystrophin (the protein product of Xp2 1 DMD/BMD) as well as the glycoproteins associated with dystrophin. The first to be excluded was the gene on chromosome 6 with homology to dystrophin and responsible for utrophin synthesis.9 However, deficiency of one of the dystrophin associated glycoproteins, the 50 kDa protein adhalin, was reported in patients with a SCARMD phenotype.'0 Two point linkage analysis between the disease gene and each of the markers was performed using the computer program Linkage.27 The gene frequency for the AR LGMD gene was taken to be 0-001. The recombination rate was assumed to be equal in males and females. A homogeneity test was carried out on the two point lod scores (15q and 2p markers) using the HOMOG program.28
Since there is genetic heterogeneity in LGMD families and not all families are large enough to give a lod score higher than 3 0, we considered that a family was likely to be linked to a candidate locus if no recombinants were identified using the closest informative marker for the region tested. In families in which the maximum positive lod score was lower than 2 0, we also verified ifrecombinants (or negative lod scores) were detected with markers from the other candidate loci.
Results
All the families were first screened for the 15q gene (pedigrees summarised in the figure). Two point lod scores for all of them are given in table 1. A positive maximum lod score at 0 = 0 0 was observed in four of these families. In one of them (family 22), a lod score of 6-8 was observed; in two others (families 17 and 47) a lod score of 2-0 was observed and a probability of 98% of linkage to 15q was estimated through the HOMOG test. In family 12, although positive, the lod score was lower owing to lack of informativeness; this family was also tested with another marker closely linked to the LGMD2A gene (D15S132) and a lod score of 2-1 at 0= 0-0 was estimated. Therefore, we considered that these four families have a high probability of being linked to the chromosome 15q gene. Linkage in families 17 2). Calf hypertrophy and asymmetry of muscle involvement was observed in some patients. However, these features varied within and between the families. 21 and 39 to be linked to the chromosome 2p gene.
These two LGMD2b families (figure) are highly inbred and from different ethnic groups (family 39 is white and family 21 is negroid).
There are 10 patients and four preclinical cases in these two pedigrees (table 2). The mean age of ascertainment was 28-9 (SD 15-6) years and the mean age of onset was 22 1 (SD 7-3) years. Only one out of the 14 patients had lost ambulation at 27 years. Serum CK was raised (on average 34-fold above normal) in all affected subjects including the one who is wheelchair bound. There was also extreme variability of clinical symptoms within and between families. For example, in family 39, with the exception of one affected patient who was wheelchair 42. In this non-consanguineous family a maximum lod score of 1-7 at 0 = 0 0 was observed (testing three affected patients, four normal sibs, and their parents); two other markers from this region were also tested in this family, but no improvement of the lod scores was obtained (D13S120, Zmax=0 5 at 0=0, and D13S143, not informative). The age of onset in the proband (II-4) was around 10 years old with complaints of difficulties in running and climbing stairs; at ascertainment, he was 16 years old and still walking with no difficulties. Serum CK activities were increased 12-fold in the proband, 17 -fold in his 18 year old sister (II2), and 40-fold in his 10 year old younger brother (II7). Careful clinical evaluation showed that the only clinical sign in II2 is difficulty in standing up from the floor, while II7 has enlargement of the calves but without any apparent weakness.
The remaining four families (families 7, 11, 16 , and 61), excluded for these three loci at 0=0 01, were tested with intragenic adhalin markers. Intragenic recombinants in the adhalin gene were not expected to be found owing to its small size.2329 Therefore, we considered that only families 7 7 and 5 years old were identified because of extremely high levels of serum CK (III 1 and III2 respectively), but both were completely asymptomatic at this age.
Discussion
The present report confirms that there are Brazilian LGMD families with a mild phenotype linked to the loci on chromosomes 15q, 2p, 17q, and one possibly linked to the 13q locus. In addition, one family with six affected patients (LG61) was excluded from the four known genes suggesting that there is at least a fifth locus responsible for mild LGMD.
All the LGMD patients included in this study have a relatively mild phenotype, which illustrates the difficulty in classifying the subforms of this muscular dystrophy based only on clinical symptoms and complementary laboratory examinations. Highly raised serum CK levels were observed only among affected and preclinical cases suggesting that a grossly raised serum CK in young people from families with LGMD patients may be considered as a preclinical diagnosis.
Preliminary clinical analysis suggests that LGMD2b may be the mildest of these four forms of LGMD. The average age of onset in
LGMD2b patients was significantly later than in the LGMD2a form (t=3-04, p<005) and none of the 2p linked patients lost ambulation before 25 years of age (table 2) .
In relation to the 13q linkage analysis, although the positive lod scores were not high enough to confirm linkage in family 42 owing to its small size, it is important to observe that negative values were estimated for all the other loci, including 17q (D17S1319, Z= -075, at 0 = 0 01). As soon as this gene is cloned, it will be extremely important to verify if the disease in these apparently 13q linked patients is the result of pathogenic mutations in this locus. If confirmed, these observations will indicate that the 13q gene may not necessarily lead to a severe phenotype, as previously reported,"9 since patients from the present family have a mild course.
Adhalin deficiency, as originally reported, should cause a severe phenotype.'0 However, all the patients from the two adhalin linked families have a relatively mild clinical course comparable to that observed in LGMD2a and
LGMD2b patients. Therefore, these data suggest that mutations in this gene may also lead to mild phenotypes.
A tentative clinical classification would be important before testing the patients for specific mutations that may cause the LGMD phenotype, in particular among the isolated cases. Only four of 57 patients from the present report were confined to a wheelchair (one aged 16, two aged 18, and one aged 27). Therefore, as in the Xp21 Duchenne and Becker muscular dystrophies, we suggest the inclusion of the age at loss of ambulation (before or after the age of 16) as an additional criterion to classify patients as severe or mild LGMD.
In conclusion, the present study confirms non-allelic heterogeneity for LGMD. Ifwe consider only the nine families with strong (or proven) evidence oflinkage to one ofthe known candidate loci, we would estimate that in our population about 44% of the mild LGMD families are caused by mutations at the 15q gene, 22% by the 2p gene, 22% by mutations in the adhalin gene, and 11% by mutations in other loci. However, if families 24 and 54 are included in the analysis, then the proportion of LGMD families caused by mutations in the 15q and 2p loci is similar, that is 33%. The finding of specific mutations in these families will be very important to confirm these data.
In order to determine the relative frequency of each of the LGMD genes (15q, 2p, 13q, and 17q) among families from different ethnic origins, as well as to identify clinical differences among these forms, it is important to test and report all available informative AR LGMD pedigrees. This approach will facilitate efforts to map and clone all of the AR LGMD loci, thereby improving the classification and understanding of this group of conditions. We thank Marta Canovas, Simone Campiotto, Antonia Cerqueira, Dr Rita de Cissia Pavanello, and Reinaldo Takata. We would also like to thank Drs K P Campbell and J Beckmann for primer sequences. 
